Literature DB >> 17703895

A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).

Hans Theodor Eich1, Axel Gossmann, Andreas Engert, Jan Kriz, Henning Bredenfeld, Katja Hansemann, Roman Skripnitchenko, Corinne Brillant, Beate Pfistner, Susanne Staar, Volker Diehl, Rolf-Peter Müller.   

Abstract

PURPOSE: The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear. The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy. A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated. METHODS AND MATERIALS: A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D).
RESULTS: In the fifth interim analysis, 1449 patients were eligible for the arm comparison with regard to RT. After a median observation time of 48 months the FFTF rate was 86% and the OS 92%. The FFTF was 95% in the RT arms A+C and 88% in the non-RT arms B+D: no sequential significant difference. One thousand and eighty four patients were evaluated by the panel. The panel defined initial bulky disease in 800 patients and residual disease in 600 patients. The panel recommended continuation of therapy according to the randomization for 934 of 1084 patients and additive RT independently from the randomization arm for 145 of 1084 patients.
CONCLUSIONS: The study showed that RT can be reduced substantially after effective chemotherapy. However, because of the irradiation of 10% of patients in the non-RT arms, equivalent effectiveness of a non-RT strategy cannot be proved. A substantial limitation of consolidative RT according to expert panel recommendations appears to be possible without reducing effectiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703895     DOI: 10.1016/j.ijrobp.2007.04.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

Authors:  Carsten Kobe; Markus Dietlein; Jeremy Franklin; Jana Markova; Andreas Lohri; Holger Amthauer; Susanne Klutmann; Wolfram H Knapp; Josee M Zijlstra; Andreas Bockisch; Matthias Weckesser; Reinhard Lorenz; Mathias Schreckenberger; Roland Bares; Hans T Eich; Rolf-Peter Mueller; Michael Fuchs; Peter Borchmann; Harald Schicha; Volker Diehl; Andreas Engert
Journal:  Blood       Date:  2008-08-29       Impact factor: 22.113

2.  Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).

Authors:  J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfart; P Lukas; A Plütschow; H Schmidberger; S Staar; M Fuchs; A Engert; H T Eich
Journal:  Strahlenther Onkol       Date:  2016-09-05       Impact factor: 3.621

3.  Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up.

Authors:  Peter H Wiernik; Fangxin Hong; John H Glick; John M Bennett
Journal:  Leuk Lymphoma       Date:  2009-10

4.  The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.

Authors:  S J Howell; C Searle; V Goode; T Gardener; K Linton; R A Cowan; M A Harris; P Hopwood; R Swindell; A Norman; J Kennedy; A Howell; A M Wardley; J A Radford
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.